M Zander

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint [The prevalence of type 2-diabetes in ethnic minorities]
    Mette Zander
    Endokrinologisk gastroenterologisk Afdeling I, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 København NV, Denmark
    Ugeskr Laeger 174:2154-8. 2012
  2. ncbi request reprint Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
    Mette Zander
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Lancet 359:824-30. 2002
  3. ncbi request reprint Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes
    Mette Zander
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetes Care 27:1910-4. 2004
  4. ncbi request reprint The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes
    M Zander
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetologia 49:369-74. 2006
  5. ncbi request reprint Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes
    M Zander
    Department of Endocrinology, Hvidovre Hospital, Denmark
    Diabetes Care 24:720-5. 2001
  6. doi request reprint Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
    Diabet Med 25:1268-75. 2008
  7. doi request reprint Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetologia 51:632-40. 2008
  8. ncbi request reprint Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes
    Kjeld Hermansen
    University Department of Endocrinology and Metabolism, Arhus Amtssygehus, Arhus, Denmark
    Metabolism 51:896-900. 2002

Collaborators

Detail Information

Publications8

  1. ncbi request reprint [The prevalence of type 2-diabetes in ethnic minorities]
    Mette Zander
    Endokrinologisk gastroenterologisk Afdeling I, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 København NV, Denmark
    Ugeskr Laeger 174:2154-8. 2012
    ..The evidence regarding the effect of initiatives targeted at ethnic minorities in Denmark is sparse. In future, clinically controlled studies in this field should be carried out...
  2. ncbi request reprint Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
    Mette Zander
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Lancet 359:824-30. 2002
    ..Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this peptide hormone in a 6-week pilot study...
  3. ncbi request reprint Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes
    Mette Zander
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetes Care 27:1910-4. 2004
    ..To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes...
  4. ncbi request reprint The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes
    M Zander
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetologia 49:369-74. 2006
    ..This study was conducted to evaluate the effect of that metabolite on plasma glucose levels in patients with type 2 diabetes...
  5. ncbi request reprint Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes
    M Zander
    Department of Endocrinology, Hvidovre Hospital, Denmark
    Diabetes Care 24:720-5. 2001
    ..0003). Combination therapy had no additional effect on appetite scores. CONCLUSIONS: Monotherapy with GLP-1 and metformin have equal effects on plasma glucose and additive effects upon combination...
  6. doi request reprint Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
    Diabet Med 25:1268-75. 2008
    ..The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose (BG) improves incretin hormone secretion and pancreatic B-cell function during a mixed meal...
  7. doi request reprint Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
    Diabetologia 51:632-40. 2008
    ..We investigated whether 4 weeks of near normalisation of blood glucose (BG) improves the potentiation of glucose-stimulated insulin secretion by GLP-1...
  8. ncbi request reprint Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes
    Kjeld Hermansen
    University Department of Endocrinology and Metabolism, Arhus Amtssygehus, Arhus, Denmark
    Metabolism 51:896-900. 2002
    ..We conclude that postprandial glycemic control was more effective with BIAsp 30 than with BHI 30, irrespective of timing of BHI 30 injection...